Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYA for liver dysfunction in NAFLD (MASLD)
jRCTs051240202Recruiting
- Sponsor
- Noster
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of 10-hydroxy-cis-12-octadecenoic acid in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Noster. Primary endpoint: ALT at 16 weeks. Started Jan 2025; status: recruiting.
02
Drugs
10-hydroxy-cis-12-octadecenoic acid
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on jRCTs051240202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240202.